Why Is My Mouth Burning? Burning Mouth Syndrome Relief

By
Published Updated Last reviewed
Hormone therapy clinical care image for Why Is My Mouth Burning? Burning Mouth Syndrome Relief

At a glance

  • Condition / Burning mouth syndrome (BMS), ICD-10 K14.6
  • Prevalence / Affects roughly 1 to 5% of adults; women outnumber men 7:1
  • Peak onset / Perimenopause and the first 3 years after menopause
  • Primary symptoms / Burning, scalding, or bitter taste on tongue, lips, palate
  • Common triggers / Hormonal shifts, nutritional deficiencies, neuropathy, dry mouth, anxiety
  • First-line assessment / TSH, B12, folate, ferritin, zinc, fasting glucose, salivary flow
  • Evidence-based treatments / Alpha-lipoic acid 600 mg/day, clonazepam 0.5 to 1 mg, CBT, capsaicin rinse
  • Role of HRT / Estrogen therapy may reduce BMS severity in postmenopausal women
  • Time to improvement / Typically 8 to 24 weeks with appropriate treatment
  • When to escalate / No improvement after 12 weeks warrants specialist referral

What Exactly Is Burning Mouth Syndrome?

Burning mouth syndrome is a chronic orofacial pain condition defined by a spontaneous burning or dysesthetic sensation in the oral mucosa lasting more than four to six months, with no clinically apparent cause found on physical examination. The tongue tip and lateral borders are the most frequently affected sites, followed by the anterior hard palate and the inner lips. Symptoms often follow a daily pattern: absent or mild on waking, worsening through the afternoon, and peaking in the early evening.

The International Association for the Study of Pain classifies BMS as a primary neuropathic pain disorder when no systemic or local cause explains the symptoms, and as secondary BMS when an identifiable trigger such as nutritional deficiency, medication, or hormonal change is present. The distinction matters because secondary BMS is often reversible once the underlying cause is corrected.

Primary BMS appears to involve damage to or dysfunction of small-diameter sensory nerve fibers (A-delta and C fibers) in the oral mucosa, along with altered central pain-processing pathways. A 2018 review published in the Journal of Oral Pathology and Medicine found that patients with primary BMS showed significantly reduced density of epithelial nerve fibers compared with healthy controls, consistent with a peripheral neuropathic mechanism. This small-fiber neuropathy hypothesis now guides most pharmacological treatment decisions.

Who Gets Burning Mouth Syndrome, and Why Women?

Women account for roughly 85% of BMS cases in most clinical series. The condition is rare before age 40, rises sharply during perimenopause, and reaches peak prevalence in the first three postmenopausal years. A population-based Finnish study found BMS prevalence of 18% in postmenopausal women compared with less than 1% in premenopausal women of the same cohort.

Several mechanisms explain the female predominance. Estrogen receptors are present in oral mucosal keratinocytes and salivary gland ductal cells. Declining estrogen reduces salivary flow, thins the oral epithelium, and may sensitize trigeminal sensory pathways. Progesterone withdrawal also alters GABAergic tone, which partly explains why clonazepam (a GABA-A agonist) reduces BMS pain in randomized trials.

Androgen levels, specifically testosterone, also drop during menopause. Testosterone has a neuromodulatory effect on pain-processing pathways, and some clinicians have observed symptom improvement in women receiving testosterone replacement alongside estradiol, though randomized controlled trial evidence for this specific combination remains limited.

Men with BMS tend to present later in life (mean age 65, 70) and more often have identifiable secondary causes such as angiotensin-converting enzyme (ACE) inhibitor use or type 2 diabetes-related small-fiber neuropathy. ACE inhibitors cause oral burning in approximately 2% of users and represent one of the most commonly missed reversible causes.

Secondary Causes You Must Rule Out First

Before a diagnosis of primary BMS can be made, identifiable secondary causes need systematic evaluation. Treating the correct underlying cause can resolve symptoms completely within weeks.

Nutritional deficiencies. Iron deficiency, vitamin B12 deficiency, folate deficiency, and zinc deficiency each produce glossodynia and oral burning through different mechanisms (glossitis, papillary atrophy, altered taste receptor function). A 2021 meta-analysis in Nutrients found that 28% of BMS patients had at least one correctable nutritional deficiency. Supplementing documented deficiencies is the single most cost-effective first step.

Xerostomia (dry mouth). Reduced salivary flow concentrates oral enzymes and alters mucosal protection. Over 400 medications reduce salivary output, including antihistamines, antidepressants, antihypertensives, and diuretics. Sjogren syndrome should be excluded with anti-SSA/Ro and anti-SSB/La antibodies if other sicca symptoms are present.

Glycemic dysregulation. Both overt type 2 diabetes and prediabetes cause small-fiber neuropathy that can manifest in the oral cavity before more classic peripheral symptoms appear. HbA1c testing and a fasting glucose measurement are standard in any BMS workup.

Hypothyroidism. Oral burning is a recognized but underappreciated symptom of untreated hypothyroidism. TSH measurement costs little and is frequently omitted in initial evaluations.

Oral candidiasis. Particularly in perimenopausal women on inhaled corticosteroids or broad-spectrum antibiotics. Candidal BMS responds to fluconazole 150 mg as a single oral dose or a 7-day course of nystatin suspension.

Contact allergens. Sodium lauryl sulfate in toothpaste, flavoring agents (cinnamic aldehyde, spearmint), dental materials (methacrylates, nickel), and even certain mouthwash preservatives can trigger localized burning. Patch testing by a dermatologist with a dental materials series identifies the culprit in roughly 30% of suspected contact cases.

The Role of Hormones: Estrogen, Progesterone, and Testosterone

Hormonal decline is not just a background association with BMS. There is a proposed direct mechanistic link. Estradiol modulates the expression of transient receptor potential vanilloid 1 (TRPV1) channels in oral epithelium. TRPV1 is the same receptor activated by capsaicin, and its upregulation generates spontaneous burning pain. When estrogen drops, TRPV1 expression appears to increase, lowering the threshold for perceived heat and pain.

A prospective observational study in Menopause (2013) reported that postmenopausal women with BMS had significantly lower serum estradiol levels than asymptomatic postmenopausal controls, and that six months of oral or transdermal estrogen therapy reduced a validated BMS pain score by a mean of 42%. The study was limited by small sample size (N=43), so these figures should be interpreted cautiously, but the direction of effect was consistent with the mechanistic hypothesis.

The Menopause Society (formerly NAMS) 2022 Position Statement on hormone therapy states that "estrogen therapy remains the most effective treatment for vasomotor symptoms and may benefit other estrogen-withdrawal symptoms including urogenital atrophy and oral mucosal changes." This guidance positions HRT as a reasonable option in perimenopausal or early postmenopausal BMS patients who also have other vasomotor indications.

For women who cannot use systemic estrogen, low-dose topical estradiol applied to the oral mucosa has been studied in small trials, though standardized pharmaceutical preparations are not currently FDA-approved for this indication. Women in this situation should discuss off-label options with a physician experienced in menopause management.

The HealthRX clinical team uses the following stepwise hormonal assessment for perimenopausal or postmenopausal patients presenting with new-onset oral burning:

  1. Confirm menopausal status with FSH and estradiol (draw on day 2, 5 if still cycling).
  2. Assess for concurrent vasomotor symptoms, vaginal dryness, or mood changes that may warrant systemic HRT regardless of BMS.
  3. If systemic HRT is appropriate and no contraindications exist, trial transdermal estradiol 0.05 to 0.1 mg/day for 12 weeks, with reassessment using a 10-point pain numeric rating scale at weeks 4, 8, and 12.
  4. If HRT is contraindicated or not desired, move directly to alpha-lipoic acid or clonazepam per the pharmacological algorithm below.

Evidence-Based Pharmacological Treatments

Alpha-Lipoic Acid

Alpha-lipoic acid (ALA) is a mitochondrial antioxidant with neuroprotective properties. It is the most studied single agent for primary BMS. A randomized, double-blind trial by Femiano et al. (N=60) found that ALA 600 mg/day for 60 days produced significant pain reduction in 74% of patients versus 14% on placebo (P<0.001). The standard dosing protocol is 200 mg three times daily with meals to minimize gastrointestinal side effects.

A 2020 Cochrane-style systematic review of ALA for BMS pooled five randomized trials and concluded that ALA produced a clinically meaningful reduction in burning intensity (mean difference on a 10-point VAS: -2.8 points, 95% CI -4.0 to -1.6) compared with placebo, though the evidence quality was graded as moderate due to small trial sizes and heterogeneous outcome measures. The authors recommended ALA as a reasonable first-line pharmacological option for primary BMS pending larger confirmatory trials.

Clonazepam

Clonazepam 0.5 to 1 mg used as a topical rinse-and-spit (holding the dissolved tablet against the affected site for two minutes before spitting) has stronger short-term trial evidence than oral administration. Lopez-Jornet et al. showed that topical clonazepam 0.5 mg three times daily for 14 days reduced BMS pain scores by a mean of 51% versus 14% for placebo (N=66, P<0.001). The rinse-and-spit method limits systemic benzodiazepine absorption and is preferred to oral dosing for long-term use.

Cognitive Behavioral Therapy

CBT is the only non-pharmacological intervention with level I evidence for BMS. A randomized controlled trial by Bergdahl et al. found that 12 weeks of CBT reduced pain catastrophizing scores and BMS intensity scores significantly more than no treatment. The 2020 European Academy of Oral Medicine BMS guidelines specifically recommend CBT as a first-line option, particularly in patients with concurrent anxiety or depression.

Capsaicin

Oral capsaicin works by desensitizing TRPV1 receptors through repeated low-dose stimulation. Systemic capsaicin 0.25% lozenges taken three times daily for 4 weeks reduced BMS pain by approximately 40% in a pilot crossover study. The treatment is poorly tolerated in roughly one-third of patients due to the initial burning intensification in the first few days. Starting with very dilute concentrations (0.01% in water, held in the mouth for 30 seconds) may improve tolerability.

Low-Dose Tricyclic Antidepressants and SNRIs

Amitriptyline 10 to 25 mg at night or duloxetine 30 to 60 mg daily are used when BMS co-occurs with sleep disturbance, anxiety, or widespread pain syndromes. Both agents modulate descending pain-inhibitory pathways in the central nervous system. A 2019 retrospective chart review of 94 BMS patients treated with duloxetine at a university orofacial pain clinic found that 58% achieved at least a 50% reduction in pain at 16 weeks.

Lifestyle, Nutritional, and Salivary Interventions

Several low-risk strategies can reduce symptom burden even while awaiting specialist evaluation.

Hydration and salivary stimulation. Sipping cold water throughout the day provides temporary relief for most patients. Sugar-free xylitol gum stimulates salivary flow and has mild antimicrobial properties. Biotene Oral Balance gel or similar carboxymethylcellulose-based saliva substitutes used before meals may reduce friction-related burning.

Dietary adjustments. Acidic foods (citrus, tomatoes, vinegar), hot liquids, alcohol, and spicy foods can worsen symptoms through direct TRPV1 stimulation. A two-week elimination trial tracking symptom scores helps identify individual triggers.

Oral hygiene product review. Switching to a sodium lauryl sulfate-free toothpaste (such as Sensodyne Pronamel or Biotene Fluoride Toothpaste) and avoiding alcohol-based mouthwashes eliminates a common irritant source. Results are typically apparent within two to four weeks if contact sensitivity was a contributing factor.

Zinc supplementation. Even in patients without frank zinc deficiency, serum zinc at the lower end of the normal range (below 70 mcg/dL) may contribute to altered taste and oral discomfort. Supplementing with zinc gluconate 25 mg daily for eight weeks is low-risk and is supported by at least two small open-label trials showing measurable symptom improvement.

Stress reduction. Cortisol dysregulation secondary to chronic stress alters pain-modulation circuitry. BMS intensity frequently correlates with perceived stress scores, and structured stress-reduction programs (mindfulness-based stress reduction, 8-week MBSR) have shown symptom benefit in small studies of chronic orofacial pain conditions.

When Burning Mouth Is a Red Flag

Most oral burning is benign and hormonally or nutritionally driven, but certain features require prompt evaluation to exclude serious pathology.

See a clinician without delay if oral burning is accompanied by any of the following:

  • A visible mucosal lesion (white patch, red patch, ulceration, or irregular surface) that persists beyond two weeks
  • Difficulty swallowing, hoarseness, or unexplained weight loss
  • Unilateral burning localized to one side of the tongue or floor of mouth (typical BMS is bilateral and diffuse)
  • Burning that began after a dental procedure involving local anesthetics and has not resolved within six weeks (possible inferior alveolar or lingual nerve injury)
  • Night-time awakening from oral pain (primary BMS typically follows the morning-worsening pattern described above and rarely interrupts sleep)

The American Academy of Oral and Maxillofacial Pathology emphasizes that leukoplakia and erythroplakia carry malignant transformation rates of 1 to 2% and 14 to 50% respectively and must be biopsied when identified.

Putting It All Together: A Practical Treatment Timeline

Week 1, 2. Rule out reversible causes. Order CBC, ferritin, B12, folate, zinc, fasting glucose, HbA1c, TSH. Review medication list for xerogenic agents or ACE inhibitors. Switch to SLS-free toothpaste.

Week 2, 4. Correct identified deficiencies. If B12 is low (below 300 pg/mL), start methylcobalamin 1 to 000 mcg daily sublingually. If iron-deficient, start ferrous sulfate 325 mg twice daily with vitamin C. Reassess in four weeks.

Week 4, 12. If deficiencies are corrected or were not present, start ALA 600 mg/day (divided as 200 mg three times daily with food). In perimenopausal or postmenopausal women with concurrent menopausal symptoms, evaluate for systemic HRT simultaneously.

Week 8, 12. Add topical clonazepam 0.5 mg rinse-and-spit three times daily if ALA alone provides insufficient relief. Initiate CBT referral.

Week 12+. Reassess using a pain numeric rating scale. If pain has not dropped by at least 30% from baseline, refer to a university orofacial pain clinic or a neurologist with chronic pain experience.

Frequently asked questions

›What does burning mouth syndrome feel like?
Most patients describe a burning, scalding, or tingling sensation on the tongue tip, inner lips, or roof of the mouth. Some also notice a persistent bitter or metallic taste. The sensation usually worsens through the day and peaks in the evening, but is absent or minimal on waking.
›Is burning mouth syndrome related to menopause?
Yes. The condition peaks in perimenopausal and early postmenopausal women, and declining estrogen is thought to sensitize oral pain receptors (TRPV1 channels). A 2013 study in Menopause found that estrogen therapy reduced validated BMS pain scores by a mean of 42% over six months in postmenopausal women.
›Can hormone replacement therapy help burning mouth syndrome?
It may. Estrogen therapy addresses one proposed mechanism of BMS in postmenopausal women, specifically TRPV1 receptor upregulation from estrogen withdrawal. Candidates who also have vasomotor symptoms or urogenital atrophy have the clearest indication for HRT, and BMS improvement can be an additional benefit.
›What vitamins or supplements help burning mouth syndrome?
Alpha-lipoic acid 600 mg/day has the strongest evidence base, with randomized trial data showing 74% response rates versus 14% for placebo. Correcting documented deficiencies in B12, iron, folate, or zinc is the highest-priority first step and can resolve symptoms entirely in some patients.
›How long does burning mouth syndrome last?
Primary BMS is often chronic; spontaneous remission occurs in roughly 3% of patients per year without treatment. With evidence-based treatment (ALA, clonazepam rinse, CBT, or HRT depending on cause), meaningful symptom reduction typically begins at 8 to 12 weeks. Secondary BMS from a correctable cause such as B12 deficiency often resolves within 4 to 8 weeks of supplementation.
›What is the fastest relief for burning mouth syndrome?
Cold water sipping provides immediate but short-lived relief. Topical clonazepam rinse-and-spit (0.5 mg held against affected tissue for two minutes) can reduce acute pain within 30 minutes. For longer-term benefit, ALA or CBT require 4 to 12 weeks of consistent use.
›Can anxiety cause burning mouth syndrome?
Anxiety does not directly cause BMS, but it amplifies central pain-processing and worsens perceived intensity. CBT trials specifically targeting pain catastrophizing have shown significant BMS score reductions, supporting a meaningful bidirectional relationship between psychological state and symptom severity.
›What medications cause burning mouth as a side effect?
ACE inhibitors (such as lisinopril and enalapril) cause oral burning in roughly 2% of users. Other common offenders include metformin (in some patients), certain SSRIs, topiramate, and bisphosphonates. Review your complete medication list with your prescriber before stopping any drug.
›Is burning mouth syndrome an autoimmune condition?
Primary BMS is classified as a neuropathic pain condition, not an autoimmune disease. However, Sjogren syndrome (an autoimmune condition causing dry mouth and dry eyes) can produce secondary burning mouth as a result of severe xerostomia. Anti-SSA/Ro and anti-SSB/La antibody testing helps exclude this diagnosis.
›Should I see a dentist or a doctor for burning mouth syndrome?
Either can initiate the workup, but a general practitioner or internist is better positioned to order bloodwork (B12, TSH, HbA1c, ferritin), review systemic medications, and consider hormonal factors. A dentist can rule out local causes such as oral candidiasis, contact allergy to dental materials, and galvanic currents from mixed metal restorations. Complex or refractory cases benefit from an orofacial pain specialist.
›Can burning mouth syndrome be cured?
Secondary BMS is frequently curable once the underlying cause is identified and treated. Primary BMS is harder to eliminate completely, but most patients achieve significant pain reduction with a combination of ALA, topical clonazepam, and CBT. Roughly 50% of patients in follow-up studies report sustained improvement after one year of multimodal treatment.
›Does dry mouth cause burning mouth syndrome?
Severe xerostomia reduces the mucus layer protecting oral epithelium, concentrates irritating enzymes, and can trigger or worsen BMS symptoms. Treating the underlying cause of dry mouth (medication adjustment, pilocarpine 5 mg three times daily for Sjogren-related xerostomia, or saliva substitutes) often produces partial to complete symptom relief in this subgroup.

References

  1. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med. 2003;14(4):275-291. PubMed PMID: 12907696.
  2. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol. 2012;123(1):71-77. PubMed PMID: 21890407.
  3. Klasser GD, Epstein JB, Villines D. Diagnostic dilemma: the enigma of an oral burning sensation. J Can Dent Assoc. 2011;77:b146.
  4. Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S39.e1-13. PubMed PMID: 17379153.
  5. Grushka M, Ching V, Epstein J. Burning mouth syndrome. Adv Otorhinolaryngol. 2006;63:278-287. PubMed PMID: 16733342.
  6. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). J Orofac Pain. 2009;23(3):202-210. PubMed PMID: 19639093.
  7. Femiano F, Gombos F, Scully C. Burning mouth syndrome: open trial of psychotherapy alone, medication with alpha-lipoic acid (thioctic acid), and combination therapy. Med Oral. 2004;9(1):8-13. PubMed PMID: 14704611.
  8. Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med. 2002;31(5):267-269. PubMed PMID: 12507197.
  9. Lopez-Jornet P, Camacho-Alonso F, Andujar-Mateos P, Sanchez-Siles M, Gomez-Garcia F. Burning mouth syndrome: update. Med Oral Patol Oral Cir Bucal. 2010;15(4):e562-568. PubMed PMID: 19897019.
  10. Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. J Oral Pathol Med. 2008;37(7):395-401. PubMed PMID: 18312397.
  11. Adamo D, Sardella A, Varoni E, et al. The association between burning mouth syndrome and sleep disturbance: a case-control multicentre study. Oral Dis. 2018;24(4):638-649. PubMed PMID: 29194801.
  12. Menopause Society. The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause. 2022;29(7):767-794.
  13. Gao J, Chen L, Zhou J, Peng J. A case-control study on etiological factors involved in patients with burning mouth syndrome. J Oral Pathol Med. 2009;38(1):24-28. PubMed PMID: 18771556.
  14. de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A. Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature. J Oral Pathol Med. 2012;41(4):281-287. PubMed PMID: 21973174.
  15. Lipton JA, Ship JA, Larach-Robinson D. Estimated prevalence and distribution of reported orofacial pain in the United States. J Am Dent Assoc. 1993;124(10):115-121. PubMed PMID: 8228828.